Annals of the Rheumatic Diseases最新文献

{"title":"Disease-modifying antirheumatic drug-free remission in psoriatic arthritis: is it attainable and sustainable? A large longitudinal study.","authors":"Selinde V J Snoeck Henkemans, Marijn Vis, Gonul Hazal Koc, Jolanda J Luime, Marc R Kok, Ilja Tchetverikov, Karen Visser, Lindy-Anne Korswagen, Jessica Bijsterbosch, Maikel van Oosterhout, Paul Baudoin, Jos H van der Kaap, Annette H M van der Helm-van Mil, Pascal H P de Jong","doi":"10.1016/j.ard.2025.04.022","DOIUrl":"10.1016/j.ard.2025.04.022","url":null,"abstract":"<p><strong>Objectives: </strong>According to current management guidelines for psoriatic arthritis (PsA) tapering of disease-modifying antirheumatic drugs (DMARDs) can be considered. However, limited data are available on complete DMARD cessation, also known as disease-modifying antirheumatic drug-free remission (DFR). Therefore, our aim was to investigate whether DFR is achievable and sustainable in PsA and to evaluate possible predictors for sustained disease-modifying antirheumatic drug-free remission (SDFR).</p><p><strong>Methods: </strong>From the Dutch southwest Early Psoriatic Arthritis cohort, all newly diagnosed patients with oligoarticular/polyarticular PsA who were treated with DMARDs were included (n = 451). Prevalence of (S)DFR and flare rates (early and late) were described. DFR was defined as the absence of clinical synovitis for ≥3 months after DMARD cessation, while for SDFR, a period of >1 year was used. Early and late flares were defined as restarting DMARD treatment ≤1 and >1 year after DMARD cessation, respectively. Subsequently, possible predictors for true SDFR, that is, SDFR without flaring were explored.</p><p><strong>Results: </strong>After a median of 5.1 years (IQR, 3.0-7.3 years), 22% of patients with PsA had reached DFR, and after reaching DFR, 4.7% had an early flare. Thus, SDFR was achieved in 14.4% of patients with PsA; 5.3% experienced a late flare, which occurred a median of 1.7 years (IQR, 1.4-2.8 years) after DMARD cessation. Eventually, 9.1% of patients reached true SDFR. Low baseline Disease Activity Index in Psoriatic Arthritis and never using biological or targeted synthetic DMARDs were independent predictors for true SDFR. At the time of true SDFR, the Health Assessment Questionnaire was similar to the general population (median, 0.12; IQR, 0-0.75).</p><p><strong>Conclusions: </strong>DFR is attainable in oligoarticular/polyarticular PsA and is sustainable in 9% of patients. However, the subgroup of patients with PsA with high disease activity at baseline and who require biological or targeted synthetic DMARDs do not achieve true SDFR. To our knowledge, this is the first study to demonstrate that chronicity can potentially be influenced in a proportion of patients with PsA.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":"1130-1139"},"PeriodicalIF":20.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144092342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spatial multiomics decipher fibroblast-macrophage dynamics in systemic sclerosis.","authors":"Zhijian Li, Aleix Rius Rigau, Wenjie Xie, Linlin Huang, Wenjing Ye, Yi-Nan Li, Alexandru-Emil Matei, Christina Bergmann, Xiaohang Shao, Hejian Zou, Jiucun Wang, Luca Pinello, Jörg H W Distler, Rui He, Minrui Liang","doi":"10.1016/j.ard.2025.04.025","DOIUrl":"10.1016/j.ard.2025.04.025","url":null,"abstract":"<p><strong>Objectives: </strong>Stromal-immune crosstalk shapes the pathogenic microenvironment of systemic sclerosis (SSc), but the spatial regulatory networks underlying fibrogenesis remain poorly defined. We aimed to explore tissue organisation and cell coordination in SSc skin, providing spatiotemporal insights into disease mechanisms and bridging the gap between omics discovery and precision medicine.</p><p><strong>Methods: </strong>We performed spatial transcriptomics on skin biopsies from 10 patients with diffuse cutaneous SSc and 4 healthy controls using the 10× Visium platform. These findings were confirmed using higher-resolution Stereo-seq transcriptomics, spatial proteomics, and single-cell RNA sequencing data from patients with SSc, SSc mouse models, and wound-healing reindeer models. In vivo and in vitro studies were conducted to validate the key regulatory pathways.</p><p><strong>Results: </strong>Fourteen skin biopsies were analysed, revealing significant expansion of fibrotic niches enriched with fibroblasts and macrophages in SSc, correlating with clinical severity. We revealed disease-specific cell states of fibroblasts and macrophages and evaluated their spatial dependency and cell-cell communication. Stratification based on signature genes enabled the identification of patients with SSc with progressive disease and treatment-nonresponsive phenotype. ACKR3 (a CXCL12 decoy receptor) was selectively expressed in myofibroblast progenitors, which diminished during differentiation towards mature myofibroblast, potentially serving to regulate CXCL12/CXCR4-mediated proinflammatory macrophage recruitment. Inhibition of CXCR4 attenuated skin and lung fibrosis in experimental fibrosis mouse models.</p><p><strong>Conclusions: </strong>Our spatially resolved atlas uncovered dynamic fibroblast-macrophage interplay as a hallmark of fibrotic niche expansion. These findings offer spatiotemporal insights into disease mechanisms and pave the way for advanced mechanistic and therapeutic studies, bridging the gap between omics discovery and precision medicine.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":"1231-1245"},"PeriodicalIF":20.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144131791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spatiotemporal distributions and regional disparities of rheumatoid arthritis in 953 global to local locations, 1980-2040, with deep learning-empowered forecasts and evaluation of interventional policies' benefits.","authors":"Wenyi Jin, Qian Wang, Cheng Jin, Mingyang Xue, Liming Pan, You Zeng, Yubiao Zhang, Fei Li, Claire Chenwen Zhong, Yutong Lu, Dong Wang, Yuanyuan Wan, Ningning Wu, Pengpeng Ye, Xintao Zhang, Baozhen Huang, Queran Lin","doi":"10.1016/j.ard.2025.04.009","DOIUrl":"10.1016/j.ard.2025.04.009","url":null,"abstract":"<p><strong>Objectives: </strong>To investigate global to local socioeconomic-driven distributions and inequalities in burdens of rheumatoid arthritis (RA) and to forecast long-term burdens.</p><p><strong>Methods: </strong>We analysed the prevalence, incidence, mortality, disability-adjusted life years (DALYs), years of life lost (YLLs), and years lived with disability (YLDs) of RA across 953 locations worldwide, as well as their inequalities and ideal frontiers. A deep-learning pipeline was developed to forecast long-term burdens with scenario simulations.</p><p><strong>Results: </strong>In 2021, RA affected 17.9 million people globally, with a 13.2% increase in incidence rate from 1990-2021, trending younger and broader. The age-standardised death rate fell 32.7% from 1980 to 2021, but global DALYs nearly doubled from 1990 to 2021. In 2021, among 652 subnational regions, West Berkshire in the UK had the highest age-standardised incidence rate (35.1; 95% uncertainty interval [UI]: 30.8-39.8). Zacatecas in Mexico had the highest age-standardised DALY rate (112.6; 95% UI: 87.2-142.7). Regions with a high sociodemographic index (SDI) bore the heaviest burden, with regional inequalities aggravating from 1990 to 2021. Over 90% of areas lagged in RA frontiers of multiple indicators. Japan uniquely showed declining trends (1990-2021), exemplified by Tokyo's age-standardised DALY rate dropping by 22.4% since 1990, unlike that in other high SDI regions. Implementing smoking control policies is forecasted to reduce RA-related deaths by 16.8% and DALYs by 20.6% among male patients in high-smoking regions like China.</p><p><strong>Conclusions: </strong>Demographic changes and uneven health infrastructure exacerbated RA burdens and disparities worldwide, with high SDI areas hardest hit while low SDI regions saw increases. Trend analysis empowered targeted policies such as localised smoking control to address these inequities.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":"1104-1116"},"PeriodicalIF":20.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144315799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to: Correspondence on 'Methotrexate continuation increases fracture risk in patients who sustained lower limb insufficiency fractures' by Dai et al.","authors":"Barbara Hauser, Andrew Merriman, Jonathan Foley, Janardhana Golla, Euan McRorie, Stuart H Ralston","doi":"10.1016/j.ard.2025.04.010","DOIUrl":"10.1016/j.ard.2025.04.010","url":null,"abstract":"","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":"e31-e32"},"PeriodicalIF":20.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143952491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary Sjögren's Disease: a review of unmet need, outcome measures, therapeutic advances and health economic impacts. Lessons from the NEw Clinical Endpoints in primary Sjögren's Syndrome: an Interventional Trial based on stratifYing patients (NECESSITY) Innovative Health Initiative (IHI).","authors":"Simon J Bowman, Raphaele Seror, Raphael Porcher, Suzanne Arends, Liseth de Wolff, Gwenny Verstappen, Valerie Devauchelle-Pensec, Sandrine Jousse-Joulin, Chiara Baldini, Michele Bombardieri, Elena Pontarini, Wolfgang Hueber, Jessica Marvel, Pushpendra Goswami, Divi Cornec, Benjamin A Fisher, Saba Nayar, Francesca Barone, Wan-Fai Ng, Jacques-Eric Gottenberg, Hendrika Bootsma, Thomas Dörner, Maggy Pincemin, Coralie Bouillot, Katherine M Hammitt, Marie Wahren-Herlenius, Joel van Roon, Gaetane Nocturne, Laurence Laigle, Philippe Moingeon, Antonia Christodoulou, Antoine G Sreih, Andre van Maurik, Wen-Hung Chen, Nicolas Wisniacki, Alena Piatrova, Roland Jonsson, Peter Gergely, Xavier Mariette","doi":"10.1016/j.ard.2025.05.004","DOIUrl":"10.1016/j.ard.2025.05.004","url":null,"abstract":"<p><p>Primary Sjögren's disease (pSjD) is an autoimmune rheumatic disease involving exocrine glands and associated with high symptom burden (dryness, fatigue, pain), systemic features and salivary gland dysfunction. B-cell hyperactivity is common, with an increased risk of mucosa-associated lymphoid tissue lymphoma. This review describes the unmet need, scientific validity of outcome measures, optimisation of clinical trial design, therapeutic advances and how clinical improvement relates to health-related quality of life, additional quality-adjusted life years and economic benefit in pSjD. It derives from the EU-funded Necessity IHI Academic-Industry collaborative Consortium project while also drawing on work by the European Alliance of Associations for Rheumatology Sjögren's task force and others. The NECESSITY Consortium, formed within the framework of the Innovative Health Initiative (IHI), comprises 20 academic partners, 1 patient group partner and 4 industry partners (NECESSITY; https://necessity-h2020.eu). Patient leaders have been closely involved, with expert advice obtained from the European Medicines Agency and the United States Food and Drug Administration during the development phase of a new outcome measure, the Sjögren's Tool for Assessing Response composite response criteria. This tool is now undergoing validation through the NECESSITY IHI clinical trial and industry-sponsored trials.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":"1068-1089"},"PeriodicalIF":20.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144315798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correspondence on '2023 ACR/EULAR antiphospholipid syndrome classification criteria'.","authors":"Yangqi Yin, Yandong Feng, Tianjiao Ma","doi":"10.1016/j.ard.2025.02.010","DOIUrl":"10.1016/j.ard.2025.02.010","url":null,"abstract":"","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":"e33-e34"},"PeriodicalIF":20.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143778897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treating juvenile dermatomyositis to target: Paediatric Rheumatology European Society/Childhood Arthritis and Rheumatology Research Alliance-endorsed recommendations from an international task force.","authors":"Angelo Ravelli, Silvia Rosina, Jayne M MacMahon, Talia Baird, Ana Isabel Rebollo-Giménez, Claas Hinze, Liza J McCann, Ann M Reed, Lisa G Rider, Matilde Arvigo, Brigitte Bader-Meunier, Claudio Bruno, Li Caifeng, Raquel Campanilho-Marques, Sara Cuccato, Chiara Fiorillo, Nikki A Hahn, Adam M Huber, Marc Jansen, Ozgur Kasapcopur, Maria Martha Katsikas, Susan Kim, Polly Livermore, Sue Maillard, Clara Malattia, Angela Nyangore Migowa, Takako Miyamae, Ruth Murphy, Rebecca Nicolai, Charalampia Papadopoulou, Clarissa Pilkington, Helga Sanner, Sujata Sawhney, Elzbieta Smolewska, Stacey E Tarvin, Georgina Tiller, Natasa Toplak, Lucy R Wedderburn, Francesca Bovis, Alessandro Consolaro, Brian M Feldman","doi":"10.1016/j.ard.2025.04.024","DOIUrl":"10.1016/j.ard.2025.04.024","url":null,"abstract":"<p><strong>Objectives: </strong>Despite the recent prognostic improvement, a sizeable proportion of patients with juvenile dermatomyositis (JDM) respond suboptimally to contemporary therapies. This study aimed to develop recommendations for treating JDM to target.</p><p><strong>Methods: </strong>A Steering Committee formulated a set of provisional recommendations based on evidence derived from a systematic literature review and a retrospective chart review of patients. These were discussed, amended, and voted on by an international Task Force, including 28 paediatric rheumatologists, 2 specialists in neuromuscular diseases, 1 dermatologist, 1 physical therapist, 1 research nurse, 2 patients with JDM, and 1 parent of a patient with JDM. Items that achieved at least an 80% majority vote were accepted as final recommendations.</p><p><strong>Results: </strong>Although the literature review did not reveal trials that compared a treat-to-target strategy with a nonsteered approach, it provided indirect evidence about specific end points that could serve as targets that facilitated development of recommendations. The group reached consensus on 7 overarching principles and 12 recommendations. It was agreed that both patients/parents and treaters should share decisions in setting treatment targets and therapeutic strategies, with inactive disease as the preferred target and minimal disease activity an alternative one. Inactive disease is targeted to be achieved within 12 months after treatment start. Interim targets include minimal and moderate clinical improvement within 6 weeks and 3 months, respectively, and normalisation of muscle strength within 6 months. High-dose glucocorticoids remain fundamental in the initial management, but progressive tapering and discontinuation within 12 months through optimisation of concomitant immunomodulatory therapy was advised. A research agenda was formulated.</p><p><strong>Conclusions: </strong>The Task Force developed recommendations for treating JDM to target, being aware that the evidence is not strong and needs to be expanded by future research. Implementation of the recommendations in clinical practice will help to reach optimal outcomes for JDM.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":"1055-1067"},"PeriodicalIF":20.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12229752/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144131794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thalidomide can effectively prevent relapse in IgG4-related disease outweighing its side effects: a multicentre, randomised, double-blinded, placebo-controlled study.","authors":"Yu Chen, Cong Ye, Pingting Yang, Wen Zhang, Lie Dai, Wei Wei, Rui Wu, Shuang Ding, Lefeng Chen, Xiuhua Wu, Jun Zhao, Chengqian Liao, Wei Sun, Hisanori Umehara, Shaozhe Cai, Lingli Dong","doi":"10.1016/j.ard.2025.01.033","DOIUrl":"10.1016/j.ard.2025.01.033","url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the effects of thalidomide in preventing disease relapse with 'zero' glucocorticoids (GCs) usage in IgG4-related disease (IgG4-RD).</p><p><strong>Methods: </strong>This was a multicentre, randomised, double-blinded, placebo-controlled study, in which eligible patients in disease active status were randomised into 2 groups (group 1: GCs+Thalidomide; group 2: GCs+Placebo) at a 1:1 ratio. The primary outcome of this trial was the disease relapse rate at month 12, whereas the secondary outcomes were the disease remission rate at month 12 and the incidence of adverse events (AEs).</p><p><strong>Results: </strong>A total of 60 patients were randomised, and 57 patients (GCs+Thalidomide: 29; GCs+Placebo: 28) finished the study per protocol. The relapse rates of the GCs+Thalidomide and GCs+Placebo groups at month 12 were 13.8% and 67.8%, respectively. A 100% response rate was observed in both treatment group, while the remission rates of the GCs+Thalidomide and GCs+Placebo groups were 75.8% and 32.1%, respectively. In total. 49 AEs were recorded in 35 participants, in which 4 were graded as moderate, and 45 were graded as mild. The risk-benefit analysis based on the evaluation of rates of disease relapse and moderate AEs within the 12-month follow-up showed a NNT (number needed to treat) of 2 and a NNH (number needed to harm) of 8 for thalidomide treatment.</p><p><strong>Conclusions: </strong>Thalidomide can effectively prevent relapse in IgG4-RD outweighing its side effects, which indicating that thalidomide can be a potential safe therapeutic option for disease relapse prevention in parallel with steroid sparing in IgG4-RD.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":"1246-1252"},"PeriodicalIF":20.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143432017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of multicriteria decision analysis in the development of candidate classification criteria for antisynthetase syndrome: analysis from the CLASS project.","authors":"Giovanni Zanframundo, Eduardo Dourado, Iazsmin Bauer-Ventura, Sara Faghihi-Kashani, Akira Yoshida, Aravinthan Loganathan, Daphne Rivero-Gallegos, Darosa Lim, Francisca Bozán, Gianluca Sambataro, Sangmee Sharon Bae, Yasuhiko Yamano, Francesco Bonella, Tamera J Corte, Tracy Jennifer Doyle, David Fiorentino, Miguel Angel Gonzalez-Gay, Marie Hudson, Masataka Kuwana, Ingrid E Lundberg, Andrew Mammen, Neil McHugh, Frederick W Miller, Carlomaurizio Montecucco, Chester V Oddis, Jorge Rojas-Serrano, Jens Schmidt, Albert Selva-O'Callaghan, Victoria P Werth, Paul Hansen, Davide Rozza, Carlo A Scirè, Garifallia Sakellariou, Yuko Kaneko, Konstantinos Triantafyllias, Santos Castañeda, Maria Laura Alberti, Martín Gerardo Greco Merino, Christopher Fiehn, Yair Molad, Marcello Govoni, Ran Nakashima, Erkan Alpsoy, Margherita Giannini, Hector Chinoy, Laure Gallay, Esther Ebstein, Julien Campagne, André Pinto Saraiva, Edoardo Conticini, Gian Domenico Sebastiani, Laura Nuño-Nuño, Salvatore Scarpato, Elena Schiopu, Matthew Parker, Massimiliano Limonta, Lorenzo Cavagna, Rohit Aggarwal","doi":"10.1016/j.ard.2025.01.050","DOIUrl":"10.1016/j.ard.2025.01.050","url":null,"abstract":"<p><strong>Objectives: </strong>To develop and evaluate the performance of multicriteria decision analysis (MCDA)-driven candidate classification criteria for antisynthetase syndrome (ASSD).</p><p><strong>Methods: </strong>A list of variables associated with ASSD was developed using a systematic literature review and then refined into an ASSD key domains and variables list by myositis and interstitial lung disease (ILD) experts. This list was used to create preferences surveys in which experts were presented with pairwise comparisons of clinical vignettes and asked to select the case that was more likely to represent ASSD. Experts' answers were analysed using the Potentially All Pairwise RanKings of all possible Alternatives method to determine the weights of the key variables to formulate the MCDA-based classification criteria. Clinical vignettes scored by the experts as consensus cases or controls and real-world data collected in participating centres were used to test the performance of candidate classification criteria using receiver operating characteristic curves and diagnostic accuracy metrics.</p><p><strong>Results: </strong>Positivity for antisynthetase antibodies had the highest weight for ASSD classification. The highest-ranked clinical manifestation was ILD, followed by myositis, mechanic's hands, joint involvement, inflammatory rashes, Raynaud phenomenon, fever, and pulmonary hypertension. The candidate classification criteria achieved high areas under the curve when applied to the consensus cases and controls and real-world patient data. Sensitivities, specificities, and positive and negative predictive values were >80%.</p><p><strong>Conclusions: </strong>The MCDA-driven candidate classification criteria were consistent with published ASSD literature and yielded high accuracy and validity.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":"1207-1220"},"PeriodicalIF":20.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143662290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relapse after anti-CD19 CAR T-cell therapy in a patient with severe rheumatoid arthritis and multiple sclerosis effectively treated by autologous stem cell transplantation.","authors":"Ann-Christin Pecher, Luca Hensen, Rebekka Schairer-Marquardt, Markus Kowarik, Vivien Richter, Wolfgang Bethge, Claudia Lengerke, Jörg Henes","doi":"10.1016/j.ard.2025.03.018","DOIUrl":"10.1016/j.ard.2025.03.018","url":null,"abstract":"","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":"1284-1286"},"PeriodicalIF":20.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143964761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}